Strategic acquisition will enable Leinco to expand its portfolio of antibody capabilities used globally for research and diagnostics. ST. LOUIS, Sept. 3, 2024 /PRNewswire/ — Leinco Technologies (“Leinco”), a trusted source of high-quality primary and secondary antibodies, recombinant…